Pharma Report 2012: Get Back in Shape

Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

2    AstraZeneca    $19.9B    up 2.1%
Global revenue: $33.6B (9th); up 0.9%

R&D spend: $5.0B (8th), up 19%; 14.9% of rev.

Top brands: Seroquel IR ($3.3B); Crestor ($3.1B); Nexium ($2.4B); Symbicort ($846M)

Planned launches: Fostamatinib (arth.): NKTR-118 (constipation)

Promotional spend: $1.3B (4th); 6.9% of rev.

Patent expirations: Seroquel IR (2012); Nexium (2014); Symbicort (2015); Crestor (2016)

AstraZeneca faces one of the steepest revenue declines of the pharma majors. Combined with a pipeline analysts consider anemic at best, analysts talk about an acquisition as being a necessary lifeboat for the firm. Most recently, AZ abandoned its depression medication known as TC-5214 after the compound missed its Phase III primary endpoint. A back-and-forth patent drama over anti-psychotic Seroquel, whose IR form goes off patent later this year, yielded a bit of good news: a US judge asserted that the extended-release version would remain covered until 2017 (although the UK High Court declared that Seroquel XR no longer had protection). The company's present outlook is one of hunkering down: besides multiple waves of job cuts, the firm shuttered at least one R&D location. Its fourth-quarter 2011 earnings call was an unvarnished one: CEO David Brennan acknowledged the pipeline is under­performing, while CFO Simon Lowth said significant revenue declines are in store.

Back to first page

Page 2 of 21
You must be a registered member of MMM to post a comment.

Content marketing is not advertising in the old sense. In its use of social media, content marketing challenges consumers while relying on their input. It is proactive and responsive to their concerns, needs and energy. Content marketing has become the new voice of marketing. Learn what you need to know and how pharma marketers can adapt to this innovative venture into social media by clicking here for access.

Email Newsletters